These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 7508844)

  • 41. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Epidemiology of benign prostatic hyperplasia: risk factors and concomitance with hypertension.
    Boyle P
    Br J Clin Pract Suppl; 1994 May; 74():18-22. PubMed ID: 7519437
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Is transition zone biopsy valuable in benign prostatic hyperplasia patients with serum prostate-specific antigen >10 ng/ml and prior negative peripheral zone biopsy?
    Abdel-Khalek M; Sheir KZ; El-Baz M; Ibrahiem el-H
    Scand J Urol Nephrol; 2005; 39(1):49-55. PubMed ID: 15764271
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The value of prostatic acid phosphatase and prostate specific antigen as serum markers in carcinoma of the prostate.
    Akdaş A; Simşek F; Ilker Y; Türkeri L; Ercan H
    Int Urol Nephrol; 1993; 25(3):271-8. PubMed ID: 7693607
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
    Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
    Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Benign prostatic hyperplasia: a review of its histogenesis and natural history.
    Oesterling JE
    Prostate Suppl; 1996; 6():67-73. PubMed ID: 8630233
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Comparison of PSAD and PSAD-TZ value in prostatic hyperplasia and prostatic cancer].
    Fu Q; Yao DH; Jiang YQ
    Zhonghua Nan Ke Xue; 2002 Dec; 8(6):411-3. PubMed ID: 12593013
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Insulin-like growth factors and risk of benign prostatic hyperplasia.
    Chokkalingam AP; Gao YT; Deng J; Stanczyk FZ; Sesterhenn IA; Mostofi FK; Fraumeni JF; Hsing AW
    Prostate; 2002 Jul; 52(2):98-105. PubMed ID: 12111701
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Autopsy study of prostatic weight and lesions in LUTH: a 12 month prospective study.
    Erinomo OO; Anunobi CC; Orah NO
    Nig Q J Hosp Med; 2013; 23(2):85-9. PubMed ID: 24579501
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prostate carcinoma risk subsequent to diagnosis of benign prostatic hyperplasia: a population-based cohort study in Sweden.
    Chokkalingam AP; Nyrén O; Johansson JE; Gridley G; McLaughlin JK; Adami HO; Hsing AW
    Cancer; 2003 Oct; 98(8):1727-34. PubMed ID: 14534890
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia.
    Soulitzis N; Karyotis I; Delakas D; Spandidos DA
    Int J Oncol; 2006 Aug; 29(2):305-14. PubMed ID: 16820871
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of anthropometric measurements and personal data parameters on benign prostatic hyperplasia and carcinoma prostate.
    Naz Z; Anjum S
    J Ayub Med Coll Abbottabad; 2010; 22(3):54-7. PubMed ID: 22338417
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Clinical study on prostatic cancer detected incidentally by transurethral resection of the prostate].
    Hayakawa T; Mitsuya H; Kojima M; Hayase Y
    Hinyokika Kiyo; 2002 Jan; 48(1):13-6. PubMed ID: 11868378
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Differences in pathological features of histological inflammation between benign prostatic hyperplasia and prostate cancer].
    Yang L; Zhao K; Zhang A; Liu LR; Liu ZH; Han P; Wei Q
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 Sep; 44(5):760-3, 768. PubMed ID: 24325107
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Clinico-pathological investigation on frequency and prognosis in patients with incidental prostatic carcinoma: preliminary report].
    Fujita T; Suzuki Y; Kanimoto Y; Okada K; Shiraishi T; Nakakuki K; Miyazaki K; Fujita Y
    Hinyokika Kiyo; 1990 Jan; 36(1):13-8. PubMed ID: 1689928
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Alterations in sphingomyelin and fatty acids in human benign prostatic hyperplasia and prostatic cancer.
    Narayan P; Dahiya R
    Biomed Biochim Acta; 1991; 50(9):1099-108. PubMed ID: 1724598
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Incidence of prostatic carcinoma.
    Sobin LH
    Scand J Urol Nephrol Suppl; 1980; 55():7-8. PubMed ID: 6163208
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Epidemiology of cancer of the prostate. Descriptive study].
    Bravo MP; de Palacio A; del Rey Calero J
    Arch Esp Urol; 1990 May; 43(4):349-52. PubMed ID: 1696450
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prostate cancer, benign prostatic hyperplasia and physical activity in Shanghai, China.
    Lacey JV; Deng J; Dosemeci M; Gao YT; Mostofi FK; Sesterhenn IA; Xie T; Hsing AW
    Int J Epidemiol; 2001 Apr; 30(2):341-9. PubMed ID: 11369740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.